Michael E. Rome - Apr 3, 2024 Form 4 Insider Report for Kinnate Biopharma Inc. (KNTE)

Role
Director
Signature
/s/ James P. Reilly, Attorney-in-Fact
Stock symbol
KNTE
Transactions as of
Apr 3, 2024
Transactions value $
$0
Form type
4
Date filed
4/5/2024, 04:55 PM
Previous filing
Jun 15, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNTE Stock Option (right to buy) Disposed to Issuer -40.5K -100% 0 Apr 3, 2024 Common Stock 40.5K $20.00 Direct F1
transaction KNTE Stock Option (right to buy) Disposed to Issuer -20.3K -100% 0 Apr 3, 2024 Common Stock 20.3K $8.38 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Michael E. Rome is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 This option was cancelled pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. in exchange for one non-transferable contingent value right ("CVR") for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.